ASCO 2010: New Treatments for CML

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.

Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.